<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05060237</url>
  </required_header>
  <id_info>
    <org_study_id>ALA-AK-CT018</org_study_id>
    <nct_id>NCT05060237</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp</brief_title>
  <official_title>A Non-randomized, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of BF-200 ALA (Ameluz®) in the Expanded Field-directed Treatment of Actinic Keratosis on the Face and Scalp With Photodynamic Therapy (PDT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biofrontera Bioscience GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biofrontera Bioscience GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate the safety and tolerability of PDT for treatment of mild&#xD;
      to severe actinic keratosis on the face and scalp in the expanded treatment field using 3&#xD;
      tubes of BF-200 ALA 10% gel (Ameluz®) in conjunction with the BF-RhodoLED® XL PDT lamp.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency and severity of adverse events (AEs), serious AEs (SAEs), and treatment emergent adverse events (TEAEs).</measure>
    <time_frame>through study completion, an average 6 weeks</time_frame>
    <description>TEAEs are defined as all AEs with onset or worsening after treatment with IMP up to Visit 5 (approx. 28 days post treatment)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of TEAEs including the breakdown of severity category (mild, moderate, severe).</measure>
    <time_frame>from treatment day (day 1) up to Visit 5 (approx. 28 days post treatment)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of new lesions (AK, NMSC such as BCC, SCC or Bowens disease, and melanoma) if they occur inside the treatment field</measure>
    <time_frame>from treatment day (day 1) up to Visit 5 (approx. 28 days post treatment)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of new lesions (AK, NMSC, and melanoma) if they occur around the treatment field at a distance of &lt;10 cm</measure>
    <time_frame>from treatment day (day 1) up to Visit 5 (approx. 28 days post treatment)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Application site skin reactions during and post PDT, assessed by the investigator</measure>
    <time_frame>from treatment day (day 1) up to Visit 5 (approx. 28 days post treatment)</time_frame>
    <description>Application site skin reaction categories: discharge, erosion, erythema, exfoliation, fissure, induration, oedema, scabbing, skin flaking, ulceration, vesicles, other; severity of AE: mild, moderate or severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Application site discomfort during and post PDT, reported by the subjects</measure>
    <time_frame>from treatment day (day 1) up to Visit 5 (approx. 28 days post treatment)</time_frame>
    <description>Application site discomfort categories: burning, hyperaesthesia, pain, paraesthesia, pruritus, stinging, warmth, other; severity of AE: mild, moderate or severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Application site pain during illumination</measure>
    <time_frame>at treatment day (day 1) after end of illumination</time_frame>
    <description>Assessed by the subjects using an 11-point numeric rating scale, where a score of 0 means &quot;no pain&quot; and a score of 10 means &quot;worst imaginable pain&quot;.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in blood pressure (systolic and diastolic)</measure>
    <time_frame>at all clinical visits through study completion, on average 6 weeks</time_frame>
    <description>[mmHg]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in pulse rate</measure>
    <time_frame>at all clinical visits through study completion, on average 6 weeks</time_frame>
    <description>[beats/min]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in body temperature</measure>
    <time_frame>at all clinical visits through study completion, on average 6 weeks</time_frame>
    <description>[°C]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Investigation of clinical chemistry parameters</measure>
    <time_frame>At screening (up to 14 days before treatment) and at Visit 5 (approx. 28 days post treatment)</time_frame>
    <description>Findings which differ from reference range and are considered to be clinically significant are to be reported</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Investigation of hematology parameters</measure>
    <time_frame>At screening (up to 14 days before treatment) and at Visit 5 (approx. 28 days post treatment)</time_frame>
    <description>Findings which differ from reference range and are considered to be clinically significant are to be reported</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Investigation of urinalysis parameters</measure>
    <time_frame>At screening (up to 14 days before treatment) and at Visit 5 (approx. 28 days post treatment)</time_frame>
    <description>Findings which differ from reference range and are considered to be clinically significant are to be reported</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical examination of head, neck, skin, lymph nodes, thorax including heart and lungs, abdomen, and musculoskeletal, peripheral vascular and nervous system status</measure>
    <time_frame>At screening (up to 14 days before treatment) and at Visit 5 (approx. 28 days post treatment)</time_frame>
    <description>Abnormal findings, considered to be clinically significant, are to be reported</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Memory tests</measure>
    <time_frame>At screening (up to 14 days before treatment) and at Visit 2 (treatment day 1)</time_frame>
    <description>Including picture- and question-based memory tasks; abnormal findings that are considered clinically significant will be documented</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neurological investigations</measure>
    <time_frame>At screening (up to 14 days before treatment) and at Visit 2 (treatment day 1)</time_frame>
    <description>Including investigation of pupils (equality), coordination (finger-nose test), gait (balance), and sensitivity (cheeks, arms, legs); abnormal findings that are considered clinically significant will be documented</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Actinic Keratosis</condition>
  <condition>Keratosis, Actinic</condition>
  <condition>Keratosis</condition>
  <arm_group>
    <arm_group_label>BF-200 ALA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical application of BF-200 ALA containing 7.8% 5-ALA (5-aminolevulinic acid).&#xD;
One single photodynamic therapy (PDT).</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>BF-200 ALA and red light LED lamp</intervention_name>
    <description>Photodynamic therapy (PDT) using BF-RhodoLED® XL (ALA-PDT, Ameluz®-PDT):&#xD;
Topical application of 3 tubes BF-200 ALA on the expanded treatment field (60 cm²), followed by red light illumination with BF-RhodoLED® XL after 3 h incubation of study medication under light-tight, occlusive dressing.</description>
    <arm_group_label>BF-200 ALA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Willingness and ability of subjects to provide informed consent and sign the Health&#xD;
             Insurance Portability and Accountability Act (HIPAA) form. A study-specific informed&#xD;
             consent and HIPAA form must be obtained in writing prior to starting any study&#xD;
             procedures.&#xD;
&#xD;
          2. Subjects with mild to severe clinically confirmed AK lesions (according to Olsen) on&#xD;
             the face and/or scalp. At least 8 mild to moderate AK lesions with a diameter of ≥4 mm&#xD;
             must be present in the treatment field. The treatment field (continuous or in several&#xD;
             patches) totaling about 60 cm2 must be located within one effective illumination area.&#xD;
             The AK lesions should be clearly distinguishable, without restrictions on the distance&#xD;
             between lesions. Lesions should have a minimal distance of 1 cm between the lesion&#xD;
             margin and the border of the treatment field.&#xD;
&#xD;
          3. All sexes, ≥18 years of age.&#xD;
&#xD;
          4. Willingness and ability to comply with study procedures, particularly willingness to&#xD;
             receive a PDT session.&#xD;
&#xD;
          5. Subjects with good general health or with clinically stable medical conditions will be&#xD;
             permitted to be included in the study. Subjects with clinically stable medical&#xD;
             conditions will be permitted for inclusion into the study if not using prohibited&#xD;
             medication.&#xD;
&#xD;
          6. Willingness to stop the use of moisturizers and any other non-medical topical&#xD;
             treatments within the treatment field at least 24 h prior to the visits.&#xD;
&#xD;
          7. Acceptance to abstain from extensive sunbathing and the use of a solarium or tanning&#xD;
             beds during the study.&#xD;
&#xD;
          8. For female subjects with reproductive potential: Negative serum pregnancy test.&#xD;
&#xD;
          9. For female subjects with reproductive potential: Effective contraception at screening&#xD;
             visit and throughout the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any known history of hypersensitivity to ALA, porphyrins or excipients of BF-200 ALA.&#xD;
&#xD;
          2. History of soy or peanut allergy.&#xD;
&#xD;
          3. Subjects with sunburn or other possible confounding skin conditions (e.g. wounds,&#xD;
             irritations, bleeding or skin infections) inside or in close proximity (&lt;10 cm&#xD;
             distance) to the treatment field.&#xD;
&#xD;
          4. Clinically significant (CS) medical conditions making implementation of the protocol&#xD;
             or interpretation of the study results difficult or impairing subject's safety such&#xD;
             as:&#xD;
&#xD;
               1. Presence of photodermatoses or porphyria&#xD;
&#xD;
               2. Metastatic tumor or tumor with high probability of metastasis&#xD;
&#xD;
               3. Infiltrating skin neoplasia (suspected or known)&#xD;
&#xD;
               4. Unstable cardiovascular disease (New York Heart Association class III, IV)&#xD;
&#xD;
               5. Unstable hematologic (including myelodysplastic syndrome), hepatic, renal,&#xD;
                  neurologic, or endocrine condition&#xD;
&#xD;
               6. Unstable collagen-vascular condition&#xD;
&#xD;
               7. Unstable gastrointestinal condition&#xD;
&#xD;
               8. Immunosuppressive condition&#xD;
&#xD;
               9. Presence of clinically significant inherited or acquired coagulation defect&#xD;
&#xD;
          5. Clinical diagnosis of atopic dermatitis, Bowen's disease, basal cell carcinoma,&#xD;
             eczema, psoriasis, rosacea, squamous cell carcinoma, other malignant or benign tumors&#xD;
             inside or in close proximity (&lt;10 cm distance) to the treatment field.&#xD;
&#xD;
          6. Presence of strong artificial pigmentation (e.g. tattoos) or any other abnormality&#xD;
             that may impact lesion assessment or light penetration in the treatment field.&#xD;
&#xD;
          7. Any physical therapy such as cryosurgery, laser therapy, electrodessication,&#xD;
             microdermabrasion, surgical removal of lesions, curettage, or treatment with chemical&#xD;
             peels such as trichloroacetic acid inside or in close proximity (&lt;10 cm distance) to&#xD;
             the treatment field within 4 weeks prior to screening.&#xD;
&#xD;
          8. Any of the topical treatments defined below within the designated periods prior to&#xD;
             screening:&#xD;
&#xD;
               1. Topical treatment with ALA or ALA esters (e.g. methyl aminolevulinic acid (MAL))&#xD;
                  or an investigational drug in- and outside the treatment field within 8 weeks.&#xD;
&#xD;
               2. Topical treatment with immunosuppressive, cytostatic or cytotoxic drugs inside or&#xD;
                  in close proximity (&lt;10 cm distance) to the treatment field within 8 weeks.&#xD;
&#xD;
               3. Start of topical administration of a medication with hypericin or other drugs&#xD;
                  with phototoxic or photoallergic potential inside or in close proximity (&lt;10 cm&#xD;
                  distance) to the treatment field within 4 weeks. Subjects may, however, be&#xD;
                  eligible if such medication was applied for more than 4 weeks prior to screening&#xD;
                  without evidence of an actual phototoxic/photoallergic reaction.&#xD;
&#xD;
          9. Any use of the systemic treatments within the designated periods prior to screening:&#xD;
&#xD;
               1. Cytostatic or cytotoxic drugs within 6 months.&#xD;
&#xD;
               2. Immunosuppressive therapies or use of ALA or ALA esters (e.g. MAL) within 12&#xD;
                  weeks.&#xD;
&#xD;
               3. Drugs known to have major organ toxicity within 8 weeks or an investigational&#xD;
                  drug.&#xD;
&#xD;
               4. Interferon or glucocorticosteroids within 6 weeks.&#xD;
&#xD;
               5. Start of intake of medication with hypericin or systemically acting drugs with&#xD;
                  phototoxic or photoallergic potential within 8 weeks prior to screening. Subjects&#xD;
                  may, however, be eligible if such medication was taken in for more than 8 weeks&#xD;
                  prior to the screening visit without evidence of an actual&#xD;
                  phototoxic/photoallergic reaction.&#xD;
&#xD;
         10. Breast feeding women.&#xD;
&#xD;
         11. Suspicion of drug or alcohol abuse.&#xD;
&#xD;
         12. Subjects unlikely to comply with protocol, e.g. inability to return for visits,&#xD;
             unlikely to complete the study, or inappropriate in the opinion of the investigator.&#xD;
&#xD;
         13. A member of study site staff or sponsor staff directly involved in the conduct of the&#xD;
             protocol or a close relative thereof.&#xD;
&#xD;
         14. Simultaneous participation in another clinical study.&#xD;
&#xD;
        Dosing day exclusion criteria:&#xD;
&#xD;
        At Visit 2 (baseline, PDT-1)&#xD;
&#xD;
        Subjects with sunburn or other possibly confounding skin conditions (e.g. wounds,&#xD;
        irritations, bleeding or skin infections) inside or in close proximity (&lt;10 cm distance) to&#xD;
        the treatment field.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Todd Schlesinger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Research Center of the Carolinas, 1364 Ashley River Road, Charleston, SC 29407, USA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Corinna Zogel, Dr.</last_name>
    <phone>+49 214 3119772207</phone>
    <email>c.zogel@biofrontera.com</email>
  </overall_contact>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 7, 2021</study_first_submitted>
  <study_first_submitted_qc>September 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 29, 2021</study_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Actinic keratosis</keyword>
  <keyword>Photodynamic therapy</keyword>
  <keyword>5-aminolevulinic acid</keyword>
  <keyword>Photosensitizing Agents</keyword>
  <keyword>Dermatologic Agents</keyword>
  <keyword>Precancerous condition</keyword>
  <keyword>Skin Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis, Actinic</mesh_term>
    <mesh_term>Keratosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aminolevulinic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

